Butylidenephthalide
Tier C — Watch / tradeButylidenephthalide
Targets：AXL, NR4A1, Telomerase
Brand：Cerebraca wafer
Indications (approved)：Glioblastoma, Glioma, Amyotrophic lateral sclerosis
Regional status
Synthetic routes & intermediates1 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
Frequently asked questions
What are the approved indications of Butylidenephthalide?
Approved indications include: Glioblastoma, Glioma, Amyotrophic lateral sclerosis.
When does the Butylidenephthalide patent expire?
No public expiry year is available for Butylidenephthalide yet; this page updates once verified.
How many synthesis routes are recorded for Butylidenephthalide?
1 synthesis routes are recorded; the shortest is 1 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Butylidenephthalide intermediates?
1 intermediate CAS of Butylidenephthalide are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Butylidenephthalide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-22